Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
Scientific presentation

Dr. Takahashi uses single-cell DNA sequencing to unambiguously identify major triple mutant clone


Koichi Takahashi, MD
Description

In this early proof-of-concept study, Dr. Koichi Takahashi from MD Anderson uses the newly available Tapestri Platform for high-throughput single-cell DNA sequencing of acute myeloid leukemia (AML) tumors. Sophisticated microfluidics and droplet technology allow researchers to encapsulate individual cells into droplets and enhance previous low-throughput single-cell technologies that relied on microwells to encapsulate single cells. In his presentation, Dr. Takahashi shows tantalizing data that comes when single nucleotide variants (SNVs) are uncovered on a per-cell basis. These data allow for the clonality of the sample to be uncovered instead of being inferred from bulk sequencing technologies. In addition, rare clones containing multiple co-occurring mutations are detected at a sensitivity of 0.1%



VIEW


Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato
(2022)
Scientific presentation
Overview on Mission Bio’s Applications
Simone Formisano
Mission Bio EU Heme Symposium (2022)
REQUEST QUOTE